SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

June 20, 2012 07:00 ET

Implant Sciences Adds Former TSA Senior Executive Mo McGowan as Advisor

Company Retains Command Consulting Group to Provide Support on Homeland Defense, Military, and Federal Government Procurement

WILMINGTON, MA--(Marketwire - Jun 20, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that United States Transportation and Security Administration (TSA) veteran Mo McGowan has been retained as an advisor to the Company through a contract with international security and intelligence consulting firm, Command Consulting Group. Mr. McGowan will provide national security expertise to advance Implant Sciences and its explosives and drugs trace detectors in the United States market. He will focus on three main segments -- military, homeland defense and security, and federal government security screening.

Mr. McGowan spent seven years at the TSA and was recognized as one of the founders of the organization. His career at the TSA culminated in being appointed Assistant Administrator for the Office of Security Operations, where he managed security operations. He was responsible for the largest non-military workforce in the U.S. government, with 53,000 personnel. His operational responsibilities included the screening of 2 million commercial air passengers per day and managing a budget in excess of $3.7 billion. Mr. McGowan was instrumental in transforming the culture and security posture of TSA's uniformed workforce. While at TSA, he also served as Deputy Assistant Administrator for Operations and General Manager for Cargo and Supply Chain Security. Prior to his TSA experience, Mr. McGowan was a Manager for the Systems Integrity Group of MCI and retired from the command level with the Richardson, Texas Police Department. He is currently a partner at Command Consulting Group.

Command Consulting Group works with a broad spectrum of clients to develop customized products and services, understand the needs of government and industry security consumers, and execute go-to-market strategies in the United States and around the world. CCG's team of operational security experts is comprised of professionals who managed and led the organizations that make up much of the current security architecture in the United States Government.

"Implant Sciences' products are an important part of the answer to numerous security challenges facing the United States. The ability to rapidly deploy systems in response to a security need provides opportunities both in homeland security and for our troops abroad," stated Mo McGowan. "I'm looking forward to helping the Company get its innovative technology into the hands of key frontline security operators."

"Mo McGowan is one of the chief architects of the TSA. He's intimately aware of the challenges the organization faces in securing our borders and the technologies required to do the job. We are very pleased to welcome him as an advisor," added Implant Sciences' President and CEO, Glenn D. Bolduc.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact